Drug information

Download files:
Other Names
CNJ-016, vaccinia immune globulin intravenous (human), vaccinia immune globulin intravenous, VIGIV
Drug Class
Immune Globulins

EA-IND protocol

Expanded access investigational new drug (EA-IND) protocol

The Centers for Disease Control and Prevention (CDC) holds an EA-IND protocol that allows for the use of vaccinia immune globulin (human) (also known as VIGIV) for the treatment or post-exposure prophylaxis (PEP) of orthopoxvirus infections, including mpox. To view the protocol, see the following link: Expanded Access IND Protocol: Use of Vaccinia Immune Globulin Intravenous (VIGIV, CNJ-016) for Treatment of Human Orthopoxvirus Infection in Adults and Children (Version 8.1; May 1, 2023).

Additionally, please visit the CDC’s Clinical Guidance webpage to access the latest information and updates related to the use of VIGIV for mpox treatment or PEP. Recommendations on the use of VIGIV for preventing and treating mpox in people with HIV are also available from the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV.